The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment
Open accessAbstract
Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. Patients with GBM often have poor prognoses, with a median survival of ∼15 months. Enhanced understanding of the molecular biology of central nervous system tumors has led to modifications in their classifications, the most recent of which classified these tumors into new categories and made some changes in their nomenclature and grading system. This review aims to give a panoramic view of the last 3 years’ findings in glioblastoma characterization, its heterogeneity, and current advances in its treatment. Several molecular parameters have been used to achieve an accurate and personalized characterization of glioblastoma in patients, including epigenetic, genetic, transcriptomic and metabolic features, as well as age‐ and sex‐related patterns and the involvement of several noncoding RNAs in glioblastoma progression. Astrocyte‐like neural stem cells and outer radial glial‐like cells from the subventricular zone have been proposed as agents involved in GBM of IDH‐wildtype origin, but this remains controversial. Glioblastoma metabolism is characterized by upregulation of the PI3K/Akt/mTOR signaling pathway, promotion of the glycolytic flux, maintenance of lipid storage, and other features. This metabolism also contributes to glioblastoma's resistance to conventional therapies. Tumor heterogeneity, a hallmark of GBM, has been shown to affect the genetic expression, modulation of metabolic pathways, and immune system evasion. GBM's aggressive invasion potential is modulated by cell‐to‐cell crosstalk within the tumor microenvironment and altered expressions of specific genes, such as ANXA2 , GBP2 , FN1 , PHIP , and GLUT3 . Nevertheless, the rising number of active clinical trials illustrates the efforts to identify new targets and drugs to treat this malignancy. Immunotherapy is still relevant for research purposes, given the amount of ongoing clinical trials based on this strategy to treat GBM, and neoantigen and nucleic acid‐based vaccines are gaining importance due to their antitumoral activity by inducing the immune response. Furthermore, there are clinical trials focused on the PI3K/Akt/mTOR axis, angiogenesis, and tumor heterogeneity for developing molecular‐targeted therapies against GBM. Other strategies, such as nanodelivery and computational models, may improve the drug pharmacokinetics and the prognosis of patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Intra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C., & Guha, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101470 · Cited by 789
Acetate is a bioenergetic substrate for human glioblastoma and brain metastases
Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K. J., Singh, D. K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S. G., Kovacs, Z., Foong, C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.025 · Cited by 760
Molecular targeted therapy of glioblastoma
Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688
Proteogenomic and metabolomic characterization of human glioblastoma
Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.006 · Cited by 661
Yang, C., Sudderth, J., Dang, T., Bachoo, R. G., McDonald, J. G., & DeBerardinis, R. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2266 · Cited by 430
Lum, J. J., Bui, T., Gruber, M., Gordan, J. D., DeBerardinis, R. J., Covello, K. L., Simon, M. C., & Thompson, C. B. (2007) · Genes & Development · doi:10.1101/gad.1529107 · Cited by 429
Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis
Lee, J.-H., Liu, R., Li, J., Zhang, C., Wang, Y., Cai, Q., Qian, X., Xia, Y., Zheng, Y., Piao, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00906-9 · Cited by 314
Mechanisms regulating glioma invasion
Paw, I., Carpenter, R. C., Watabe, K., Debinski, W., & Lo, H.-W. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.015 · Cited by 306
Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1137-5 · Cited by 303
Robert, S. M., Buckingham, S. C., Campbell, S. L., Robel, S., Holt, K. T., Ogunrinu-Babarinde, T., Warren, P. P., White, D. M., Reid, M. A., Eschbacher, J. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8103 · Cited by 301 · cited 2×
“3 histone A; HDAC1, Histone deacetylase 1; HDACIs, Histone deacetylase inhibitors; HER-2, Human epidermal growth factor receptor 2; HGGs, High-grade gliomas; Hh, Hedgehog; HIF, Hypoxia inducible factor; HIF-1α, Hypoxia inducible factor 1 subunit alpha; HIF-2α, Hypoxia inducible factor 2 subunit alpha; HK2, Hexokinase…”
BackgroundTumor Cell Invasion in Glioblastoma
Vollmann-Zwerenz, A., Leidgens, V., Feliciello, G., Klein, C. A., & Hau, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061932 · Cited by 257
Circulating biomarkers in patients with glioblastoma
Müller Bark, J., Kulasinghe, A., Chua, B., Day, B. W., & Punyadeera, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0603-6 · Cited by 252
Golan-Gerstl, R., Cohen, M., Shilo, A., Suh, S.-S., Bakàcs, A., Coppola, L., & Karni, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4410 · Cited by 232
The Role of Annexin A2 in Tumorigenesis and Cancer Progression
Lokman, N. A., Ween, M. P., Oehler, M. K., & Ricciardelli, C. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0064-9 · Cited by 230
Bronisz, A., Wang, Y., Nowicki, M. O., Peruzzi, P., Ansari, K. I., Ogawa, D., Balaj, L., De Rienzo, G., Mineo, M., Nakano, I., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2650 · Cited by 222
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches
Uddin, M. S., Mamun, A. A., Alghamdi, B. S., Tewari, D., Jeandet, P., Sarwar, M. S., & Ashraf, G. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.015 · Cited by 213
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
Becker, A., Sells, B., Haque, S., & Chakravarti, A. (2021) · Cancers · doi:10.3390/cancers13040761 · Cited by 212
Krauze, A. V., Myrehaug, S. D., Chang, M. G., Holdford, D. J., Smith, S., Shih, J., Tofilon, P. J., Fine, H. A., & Camphausen, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.04.038 · Cited by 204
Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J.-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 198
Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells
Wang, X., Yang, K., Wu, Q., Kim, L. J. Y., Morton, A. R., Gimple, R. C., Prager, B. C., Shi, Y., Zhou, W., Bhargava, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau4972 · Cited by 193
Delgado‐Martín, B., & Medina, M. Á. (2020) · Advanced Science · doi:10.1002/advs.201902971 · Cited by 191
Self-citationHedgehog Signaling and Truncated GLI1 in Cancer
Doheny, D., Manore, S. G., Wong, G. L., & Lo, H.-W. (2020) · Cells · doi:10.3390/cells9092114 · Cited by 189
Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population
Grech, N., Dalli, T., Mizzi, S., Meilak, L., Calleja, N., & Zrinzo, A. (2020) · Cureus · doi:10.7759/cureus.8195 · Cited by 182
Gimple, R. C., Kidwell, R. L., Kim, L. J. Y., Sun, T., Gromovsky, A. D., Wu, Q., Wolf, M., Lv, D., Bhargava, S., Jiang, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0061 · Cited by 181
Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
Jena, L., McErlean, E., & McCarthy, H. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00679-2 · Cited by 176
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Bagley, S. J., Kothari, S., Rahman, R., Lee, E. Q., Dunn, G. P., Galanis, E., Chang, S. M., Nabors, L. B., Ahluwalia, M. S., Stupp, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2750 · Cited by 171
Roth, W., Wild-Bode, C., Platten, M., Grimmel, C., Melkonyan, H. S., Dichgans, J., & Weller, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203783 · Cited by 170
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2644-z · Cited by 163
Applications of radiomics and machine learning for radiotherapy of malignant brain tumors
Kocher, M., Ruge, M. I., Galldiks, N., & Lohmann, P. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-020-01626-8 · Cited by 162
Extracellular Vesicles in Glioblastoma Tumor Microenvironment
Yekula, A., Yekula, A., Muralidharan, K., Kang, K. M., Carter, B. S., & Balaj, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03137 · Cited by 151
Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
Colardo, M., Segatto, M., & Bartolomeo, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094899 · Cited by 149
Advances in the management of glioblastoma
Ma, R., TAPHOORN, M. J. B., & Plaha, P. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325334 · Cited by 142
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 141
Reddy, S., Tatiparti, K., Sau, S., & Iyer, A. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.008 · Cited by 136
Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches
Shakya, S., Gromovsky, A. D., Hale, J. S., Knudsen, A. M., Prager, B. C., Wallace, L. C., Penalva, L. O. F., Ivanova, P. T., Brown, H. A., Kristensen, B. W., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01205-7 · Cited by 134
Galldiks, N., Niyazi, M., Grosu, A., Köcher, M., Langen, K., Law, I. G., Minniti, G. C., Kim, M. M., Tsien, C. I., Dhermain, F. G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab013 · Cited by 127
The Roles of miRNA in Glioblastoma Tumor Cell Communication: Diplomatic and Aggressive Negotiations
Buruiană, A., Florian, I. Ş., Florian, I. A., Timiș, T. L., Mihu, C. M., Miclăuș, M., Oșan, S., Hrapșa, I., Cataniciu, R. C., Farcas, M. F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061950 · Cited by 121
Mirzaei, S., Mahabady, M. K., Zabolian, A., Abbaspour, A., Fallahzadeh, P., Noori, M., Hashemi, F., Hushmandi, K., Daneshi, S., Kumar, A. P., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119368 · Cited by 116
Establishment of age group classification for risk stratification in glioma patients
Lin, Z., Yang, R., Li, K., Yi, G., Li, Z., Guo, J., Zhang, Z., Junxiang, P., Liu, Y., Qi, S., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01888-w · Cited by 114
Matarredona, E. R., & Pastor, Á. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00779 · Cited by 112
Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
Kan, L. K., Drummond, K. J., Hunn, M., Williams, D. J., O'Brien, T. J., & Monif, M. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000069 · Cited by 109
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
Frederico, S. C., Hancock, J. C., Brettschneider, E. E. S., Ratnam, N. M., Gilbert, M. R., & Terabe, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672508 · Cited by 108
Cell Lineage-Based Stratification for Glioblastoma
Wang, Z., Sun, D., Chen, Y.-J., Xie, X., Shi, Y., Tabar, V. S., Brennan, C., Bale, T., Jayewickreme, C. D., Laks, D. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.003 · Cited by 106
Corrêa, B., Araujo, P. R. D., Qiao, M., Burns, S. C., Chen, C., Schlegel, R., Agarwal, S., Galante, P. A. F., & Penalva, L. O. F. (2016) · Genome biology · doi:10.1186/s13059-016-0990-4 · Cited by 103
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype
Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K.-H., Schlotter, M., Felsberg, J., Mangei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20225-w · Cited by 101
Kurç, T., Bakas, S., Ren, X., Bagari, A., Momeni, A., Huang, Y., Zhang, L., Kumar, A., Thibault, M., Qi, Q., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00027 · Cited by 98
Han, L., & Kamdar, M. R. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0031 · Cited by 97
Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression
Ferrarese, R., Harsh, G. R., Yadav, A. K., Bug, E., Maticzka, D., Reichardt, W., Dombrowski, S. M., Miller, T. E., Masilamani, A. P., Dai, F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68836 · Cited by 95
Glioblastoma Therapy in the Age of Molecular Medicine
Geraldo, L. H., Garcia, C., da Fonseca, A. C. C., Dubois, L. G., Spohr, T. C. L. D. S. E., Matias, D., Magalhães, E. S. D. C., do Amaral, R. F., da Rosa, B. G., Grimaldi, I., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.002 · Cited by 95
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives
Gatto, L., Franceschi, E., Nunno, V. D., Tosoni, A., Lodi, R., & Brandes, A. A. (2021) · The Oncologist · doi:10.1002/onco.13858 · Cited by 94
Izaguirre, D. I., Zhu, W., Hai, T., Beird, H. C., Krahe, R., & Cote, G. J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20859 · Cited by 92
Calabrese, E., Villanueva-Meyer, J. E., & Cha, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-68857-8 · Cited by 91
Sperry, J., Condro, M. C., Guo, L., Braas, D., VanderVeer-Harris, N., Kim, K. K. O., Pope, W. B., Divakaruni, A. S., Lai, A., Christofk, H. R., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101453 · Cited by 91
GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway
Yu, S., Yu, X., Sun, L., Zheng, Y., Chen, L., Xu, H., Jin, J., Lan, Q., Chen, C. C., & Li, M. (2020) · Oncogene · doi:10.1038/s41388-020-1348-7 · Cited by 88
Deep Learning AI Applications in the Imaging of Glioma
Zlochower, A. B., Chow, D. S., Chang, P. D., Khatri, D., Boockvar, J. A., & Filippi, C. G. (2020) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000237 · Cited by 84
Cancer Stem Cells in Glioblastoma Multiforme
Bradshaw, A., Wickremesekera, A., Brasch, H. D., Chibnall, A. M., Davis, P. F., Tan, S. T., & Itinteang, T. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00048 · Cited by 81
Proteogenomics of glioblastoma associates molecular patterns with survival
Arad, G., Ofek, P., Yeini, E., Mardamshina, M., Danilevsky, A., Shomron, N., Grossman, R., Satchi‐Fainaro, R., & Geiger, T. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108787 · Cited by 79
Schröder, A., Bauer, K., Spanier, G., Proff, P., Wolf, M. F., & Kirschneck, C. (2018) · Journal of Orofacial Orthopedics / Fortschritte der Kieferorthopädie · doi:10.1007/s00056-018-0145-1 · Cited by 78
Zhao, X., Zhou, L., Li, X., Ni, J., Chen, P., Ma, R., Wu, J., & Feng, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1710 · Cited by 78
Roles of Non-coding RNAs and Angiogenesis in Glioblastoma
Balandeh, E., Mohammadshafie, K., Mahmoudi, Y., Pourhanifeh, M. H., Rajabi, A., Bahabadi, Z. R., Mohammadi, A. H., Rahimian, N., Hamblin, M. R., & Mirzaei, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.716462 · Cited by 75
Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy
Birkó, Z., Nagy, B., Klekner, Á., & Virga, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207522 · Cited by 71
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
A comparative study for glioma classification using deep convolutional neural networks
Özcan, H., Emiroğlu, B. G., Sabuncuoğlu, H., Özdoğan, S., Soyer, A., & Saygı, T. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021080 · Cited by 60
Sudre, C. H., Panovska‐Griffiths, J., Sanverdi, E., Brandner, S., Katsaros, V. K., Stranjalis, G., Pizzini, F. B., Ghimenton, C., Surlan-Popović, K., Avsenik, J., et al. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01163-5 · Cited by 59
Dejaegher, J., Solie, L., Hunin, Z., Sciot, R., Capper, D., Siewert, C., Cauter, S. V., Wilms, G., van Loon, J., Ectors, N., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa247 · Cited by 59
Montemurro, N. (2019) · Journal of Neurological Surgery Part A Central European Neurosurgery · doi:10.1055/s-0039-1688911 · Cited by 53
Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone
Yoon, S., Park, J., Jang, D.-S., Kim, H. J., Lee, J. H., Jo, E., Choi, R. J., Shim, J.-K., Moon, J. H., Kim, E. H., et al. (2019) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2019.0129 · Cited by 53
Ohno, M., Matsuzaki, J., Kawauchi, J., Aoki, Y., Miura, J., Takizawa, S., Kato, K., Sakamoto, H., Matsushita, Y., Takahashi, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16953 · Cited by 53
A map of the altered glioma metabolism
Deshmukh, R. S., Allega, M. F., & Tardito, S. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.011 · Cited by 53
Lee, H., Park, I., Park, K. H., An, S., Woo, S., Jin, H., Chung, H. Y., Lee, S., Gwak, H., Hong, Y., et al. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20312 · Cited by 52
Mater, D. V., Gururangan, S., Becher, O. J., Campagne, O., Leary, S. E. S., Phillips, J. J., Huang, J., Lin, T., Poussaint, T. Y., Goldman, S., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28879 · Cited by 51
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex
de Semir, D., Bezrookove, V., Nosrati, M., Scanlon, K. R., Singer, E. A., Judkins, J., Rieken, C., Wu, C., Shen, J., Schmudermayer, C., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914505117 · Cited by 49
Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!
Fontanilles, M., Durán-Peña, A., & Idbaïh, A. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0820-z · Cited by 46
FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles
Ricklefs, F. L., Maire, C. L., Matschke, J., Dührsen, L., Sauvigny, T., Holz, M., Kolbe, K., Peine, S., Herold‐Mende, C. C., Carter, B. S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061931 · Cited by 46
Glioblastoma multiforme: a multi-omics analysis of driver genes and tumour heterogeneity
Herrera-Oropeza, G. E., Angulo‐Rojo, C., Gástelum-López, S. A., Varela‐Echavarría, A., Hernández-Rosales, M., & Aviña‐Padilla, K. (2021) · Interface Focus · doi:10.1098/rsfs.2020.0072 · Cited by 46
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Singh, K., Batich, K. A., Wen, P. Y., Tan, A. C., Bagley, S. J., Lim, M. K., Platten, M., Colman, H., Ashley, D. M., Chang, S. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2681 · Cited by 42
The Subventricular Zone, a Hideout for Adult and Pediatric High-Grade Glioma Stem Cells
Lombard, A., Digregorio, M., Delcamp, C., Rogister, B., Piette, C., & Coppieters, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614930 · Cited by 41
Classification of glioma based on prognostic alternative splicing
Li, Y., Ren, Z., Peng, Y.-P., Li, K., Wang, X., Huang, G., Qi, S., & Liu, Y. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0603-7 · Cited by 39
A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1
Libby, C. J., Sajina, G. C., Benavides, G. A., Fisher, J. L., Williford, S. E., Zhang, S., Tran, A. N., Gordon, E. R., Jones, A. B., Tuy, K., et al. (2021) · Cell Adhesion & Migration · doi:10.1080/19336918.2021.1903684 · Cited by 38
Matsumoto, Y., Ichikawa, T., Kurozumi, K., Otani, Y., Fujimura, A., Fujii, K., Tomita, Y., Hattori, Y., Uneda, A., Tsuboi, N., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00916-7 · Cited by 37
MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma
Chai, Y., Wang, C., Liu, W., Fan, Y., & Zhang, Y. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03226-8 · Cited by 35
Im, S., Hyeon, J., Rha, E. Y., Lee, J., Choi, H., Jung, Y., & Kim, T. J. (2021) · Sensors · doi:10.3390/s21103500 · Cited by 34
Randles, A. P., Wirsching, H., Dean, J., Cheng, Y.-K., Emerson, S., Pattwell, S. S., Holland, E. C., & Michor, F. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00710-3 · Cited by 33
Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics
Wu, Z., Dai, L., Tang, K., Ma, Y., Song, B., Zhang, Y., Li, J., Lui, S., Gong, Q., & Wu, M. C. (2021) · Regenerative Biomaterials · doi:10.1093/rb/rbab062 · Cited by 33
Valdebenito, S., Damico, D. C. S., & Eugenín, E. A. (2019) · Cancer Reports · doi:10.1002/cnr2.1220 · Cited by 29
Integrated Analysis to Evaluate the Prognostic Value of Signature mRNAs in Glioblastoma Multiforme
Yang, J., Wang, L., Zhou, X., Wu, L., Liu, B., Wang, J., Tian, D., Xiong, X., & Chen, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00253 · Cited by 27
Novel Vaccines for Glioblastoma: Clinical Update and Perspective
Winograd, E. K., Ciesielski, M. J., & Fenstermaker, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0059 · Cited by 26
FABP7 Facilitates Uptake of Docosahexaenoic Acid in Glioblastoma Neural Stem-like Cells
Choi, W.-S., Xu, X., Goruk, S., Wang, Y., Patel, S., Chow, M., Field, C. J., & Godbout, R. (2021) · Nutrients · doi:10.3390/nu13082664 · Cited by 26
Modeling invasion patterns in the glioblastoma battlefield
Conte, M., Casas‐Tintó, S., & Soler, J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008632 · Cited by 25
Wang, Z., Gao, L., Guo, X., Lian, W., Deng, K., & Xing, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576996 · Cited by 23
Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
Paranthaman, S., Shivananjegowda, M. G., Mahadev, M., Moin, A., Shivakumar, H. N., Nanjaiah, N. D., Chidambaram, S. B., & Gowda, D. V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121198 · Cited by 23
Herrera-Rios, D., Li, G., Khan, D., Tsiampali, J., Nickel, A., Aretz, P., Hewera, M., Suwala, A. K., Jiang, T., Steiger, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72480-y · Cited by 22
Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
Cano-Galiano, A., Oudin, A., Fack, F., Allega, M. F., Sumpton, D. P., Martínez-García, E., Dittmar, G., Hau, A., Falco, A. D., Herold‐Mende, C. C., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab057 · Cited by 21
The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme
Bhatia, S., Bukkapatnam, S., Court, B. V., Phan, A. V., Oweida, A. J., Gadwa, J., Mueller, A. C., Piper, M., Darragh, L. B., Nguyen, D., et al. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23237 · Cited by 20
Liu, L., Choi, J. H., Yim, H., Choi, J. S., Park, B. D., Cho, S. J., & Lee, S. K. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.014 · Cited by 19
Jean-Quartier, C., Jeanquartier, F., Ridvan, A., Kargl, M., Mirza, T., Stangl, T., Markaĉ, R., Jurada, M., & Holzinger, A. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01420-1 · Cited by 19
Ibrahim, A. N., Yamashita, D., Anderson, J. C., Abdelrashid, M., Alwakeal, A., Estévez-Ordoñez, D., Komarova, S., Markert, J. M., Goidts, V., Willey, C. D., et al. (2019) · Journal of neurosurgery · doi:10.3171/2019.7.jns191376 · Cited by 17
Nano delivery of natural substances as prospective autophagy modulators in glioblastoma
Agarwal, S., & Maekawa, T. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102270 · Cited by 17
Primary glioblastoma transcriptome data analysis for screening survival‐related genes
Yang, Y., Yan, R., Zhang, L., Meng, X., & Sun, W. C. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29425 · Cited by 16
Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth
Doan, P., Nguyen, P., Murugesan, A., Subramanian, K., Saravanan, K. M., Vignesh, K., Abraham, B. G., Stringer, B. W., Kadalmani, B., Yli-Harja, O. P., et al. (2021) · Cancers · doi:10.3390/cancers13153773 · Cited by 16
Gaps and Doubts in Search to Recognize Glioblastoma Cellular Origin and Tumor Initiating Cells
Włodarczyk, A., Grot, D., Stoczyńska-Fidelus, E., & Rieske, P. (2020) · Journal of Oncology · doi:10.1155/2020/6783627 · Cited by 14
Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas
Ruiz, F., Gennaro, M., Bastone, L., Godoy, A., Torruella, M., & Pérez, G. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2312 · Cited by 14
Singer, L., Feldman, A. Z., Buerki, R. A., Horbinski, C., Lukas, R. V., & Stupp, R. (2021) · Chinese Clinical Oncology · doi:10.21037/cco-21-33 · Cited by 14
Tran, P. M. H., Tran, L. K. H., Nechtman, J., dos Santos, B., Purohit, S. B., Satter, K. B., Dun, B., Kolhe, R. B., Sharma, S., Bollag, R. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77777-6 · Cited by 12
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Biomedicines · doi:10.3390/biomedicines9060619 · Cited by 12
Saito, N., Hirai, N., Aoki, K., Sato, S., Suzuki, R., Hiramoto, Y., Fujita, S., Nakayama, H., Hayashi, M., Sakurai, T., et al. (2019) · Cancers · doi:10.3390/cancers11101564 · Cited by 10
Jankowska, S., Lewandowska, M., Masztalewicz, M., Sagan, L. M., Nowacki, P., & Urasińska, E. (2021) · Polish Journal of Pathology · doi:10.5114/pjp.2021.106439 · Cited by 10
Cai, Z., Yu, C., Li, S., Wang, C., Fan, Y., Ji, Q., Chen, F., & Li, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685823 · Cited by 10
Characterization of molecular pathways for targeting therapy in glioblastoma
Wagle, N. A., Nguyen, M., Carrillo, J., Truong, J., Dobrawa, L., & Kesari, S. (2020) · Chinese Clinical Oncology · doi:10.21037/cco-20-124 · Cited by 9
Aberrations of Genomic Imprinting in Glioblastoma Formation
Lozano-Ureña, A., Jiménez-Villalba, E., Pinedo‐Serrano, A., Jordán‐Pla, A., Kirstein, M., & Ferrón, S. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.630482 · Cited by 9
Salvati, M., Tariciotti, L., Brunetto, G. M. F., Gallo, G., Santoro, F., Frati, A., & Santoro, A. (2020) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2020.100697 · Cited by 4
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metadata
- Authors
- Verdugo, E., Puerto, I., & Medina, M. Á.
- Venue
- Cancer Communications
- Published
- 2022-09-21
- Volume
- 42
- Issue
- 11
- Pages
- 1083-1111
- ISSN
- 1000-467X (ISSN-L)
- 2523-3548
- OpenAlex
- W4296959114
- Cited by
- 253
- References
- 123
- FWCI
- 24.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.